Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrahydrocannabinolic acid + cannabidiolic acid
- Development stage
- Preclinical
- Lead developer
- Weed Holdings
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal, Inhalation, Oromucosal, Topical
01
Overview
This cannabinoid formulation is a preclinical-stage therapeutic being developed by Weed Holdings (WEED, Inc.). It utilizes a proprietary electrochemical bonding process to combine tetrahydrocannabinolic acid (THCa) and cannabidiolic acid (CBDa). Unlike their decarboxylated counterparts, tetrahydrocannabinol (THC) and cannabidiol (CBD), these acidic precursors are non-psychoactive. The formulation is designed to harness the therapeutic potential of cannabinoids for various medical applications, such as pain and inflammation, while avoiding the intoxicating effects associated with activated THC. The electrochemical bonding is intended to create stable, non-psychoactive cannabinoid medicines by potentially altering the delivery or interaction of the acidic cannabinoids with their biological targets.
- Other names
- THCa + CBDa formulationelectrochemical bonded THCa and CBDaWeed Holdings cannabinoid formulation
02
Targets
CNR2 (Cannabinoid receptor type 2)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on tetrahydrocannabinolic acid + cannabidiolic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrahydrocannabinolic acid + cannabidiolic acid.